Sugi Predict

Sugi Predict / Compounds / SCHEMBL4014126

SCHEMBL4014126

SCHEMBL4014126

c1ccc2nc3cccc(-c4cccc5nc6ccccc6cc45)c3cc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.64
▸ ALDH1A1 P00352 5/20 0.64
▸ KDM4E B2RXH2 5/20 0.64
▸ RAB9A P51151 5/20 0.64
▸ GLA P06280 4/20 0.64
▸ HPGD P15428 3/20 0.64
▸ NPC1 O15118 3/20 0.64
▸ GAA P10253 2/20 0.64
▸ LMNA P02545 1/20 0.64
▸ POLB P06746 1/20 0.64
▸ PTBP1 P26599 1/20 0.64
▸ RCE1 Q9Y256 1/20 0.64
▸ MAPT P10636 5/20 0.61
▸ ACHE P22303 2/20 0.61
▸ NQO2 P16083 2/20 0.46
▸ MEN1 O00255 4/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ TP53 P04637 2/20 0.46
▸ CYP3A4 P08684 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1187275 0.94 ALDH1A1 (0.58) KMT2AALDH1A1KDM4ERAB9AGLA
SCHEMBL1187919 0.92 ALDH1A1 (0.56) KMT2AALDH1A1KDM4ERAB9AGLA
SCHEMBL28917948 0.90 ALDH1A1 (0.55) KMT2AALDH1A1KDM4ERAB9AGLA
SCHEMBL1122659 0.90 ALDH1A1 (0.58) KMT2AALDH1A1KDM4ERAB9AGLA
SCHEMBL28229302 0.89 ALDH1A1 (0.53) KMT2AALDH1A1KDM4ERAB9AGLA
SCHEMBL3109534 0.89 ALDH1A1 (0.73) KMT2AALDH1A1KDM4ERAB9AGLA
SCHEMBL27956660 0.89 MBNL1 (0.54) KMT2AALDH1A1KDM4ERAB9AGLA
SCHEMBL28265823 0.89 ALDH1A1 (0.53) KMT2AALDH1A1KDM4ERAB9AGLA
SCHEMBL28854322 0.89 ALDH1A1 (0.54) KMT2AALDH1A1KDM4ERAB9AGLA
Hydrochloric Acid SCHEMBL3913858 0.88 ALDH1A1 (0.56) KMT2AALDH1A1KDM4ERAB9AGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116297764-A Preparation method of polymer film layer for biosensor 深圳硅基传感科技有限公司 2023-06-23 — — CN claimed
CN-116297765-A Polymer membrane for biosensor 深圳硅基传感科技有限公司 2023-06-23 — — CN claimed
US-20050080260-A1 Preparation of prodrugs for selective drug delivery LUMINIDE 2005-04-14 — — US claimed
US-20020034828-A1 NOVEL 10,10'-SUBSTITUTED-9,9'-BIACRIDINE LUMINESCENT MOLECULES AND THEIR PREPARATION PIERCE CHEMICAL COMPANY 2002-03-21 — — US claimed
EP-1026156-A2 Novel 10, 10'-substituted-9,9'-biacridine luminescent molecules and their preparation PIERCE CHEMICAL COMPANY (US) 2000-08-09 — — EP claimed
US-5773592-A COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED MILLS RANDELL LEE (US) 1998-06-30 — — US claimed
WO-2023199919-A1 FLOW CYTOMETER, DETERMINATION METHOD, AND PROGRAM シンクサイト株式会社 2023-10-19 — — WO disclosed
CN-113831343-B Thermal activity delayed fluorescent material based on imidazopyrazine receptor material, preparation method and application thereof 安徽秀朗新材料科技有限公司 2023-09-05 — — CN disclosed
US-20220348750-A1 BETA NUCLEATED HETEROPHASIC POLYPROPYLENE COMPOSITION BOREALIS AG (AT) 2022-11-03 — — US disclosed
EP-3990900-A1 OXIDASE-BASED CHEMILUMINESCENCE ASSAY OF PHAGOCYTIC LEUKOCYTES IN WHOLE BLOOD AND BODY FLUIDS APPLICABLE TO POINT-OF-CARE (POC) DIAGNOSTIC TESTING POINT-OF-CARE (POC) MEASUREMENT OF ABSOLUTE NEUTROPHIL FUNCTION (ANF) Binary LLC (US) 2022-05-04 — — EP disclosed
WO-2020263571-A1 OXIDASE-BASED CHEMILUMINESCENCE ASSAY OF PHAGOCYTIC LEUKOCYTES IN WHOLE BLOOD AND BODY FLUIDS APPLICABLE TO POINT-OF-CARE (POC) DIAGNOSTIC TESTING POINT-OF-CARE (POC) MEASUREMENT OF ABSOLUTE NEUTROPHIL FUNCTION (ANF) BINARY LLC (US) 2020-12-30 — — WO disclosed
US-20170101669-A1 Nucleic Acid Based Sensor and Methods Thereof NATIONAL CENTRE FOR BIOLOGICAL SCIENCES (IN) 2017-04-13 — — US disclosed
WO-2015159122-A1 NUCLEIC ACID BASED SENSOR AND METHODS THEREOF NATIONAL CENTRE FOR BIOLOGICAL SCIENCES (IN) 2015-10-22 — — WO disclosed
EP-0766825-A1 PREPARATION OF DERIVATIZED 10,10'-SUBSTITUTED-9,9'-BIACRIDINE LUMINESCENT MOLECULES AND SIGNAL SOLUTIONS Katsilometes, George, W. (US) 1997-04-09 — — EP disclosed
WO-1996000392-A1 PREPARATION OF DERIVATIZED 10,10'-SUBSTITUTED-9,9'-BIACRIDINE LUMINESCENT MOLECULES AND SIGNAL SOLUTIONS KATSILOMETES GEORGE W (US) 1996-01-04 — — WO disclosed
US-5428163-A Luminides; chemiluminescence; redox system, releasing free drug MILLS RANDELL L (US) 1995-06-27 — — US disclosed
EP-0414730-A4 LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS — 1993-06-16 — — EP disclosed
EP-0414730-A1 LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS Mills, Randell L. (US) 1991-03-06 — — EP disclosed
WO-1989009833-A1 LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS MILLS RANDELL L (US) 1989-10-19 — — WO disclosed
EP-0137515-A2 Bioluminescent immunoassays THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1985-04-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080260-A1 Preparation of prodrugs for selective drug delivery APEH, PAH, ALAD KMT2A 3377/4885ALDH1A1 61/4885KDM4E 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.